PDS Biotechnology Corporation
NASDAQ:PDSB
3.28 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.057 | 0.049 | 0.246 | 0.176 | 0.098 | 0.069 | 0.183 | 0.1 | 0.053 | 0 | 0 |
| Gross Profit
| -0.057 | -0.049 | -0.246 | -0.176 | -0.098 | -0.069 | -0.183 | -0.1 | -0.053 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 27.763 | 29.431 | 11.255 | 7.924 | 6.1 | 16.069 | 34.312 | 24.825 | 17.84 | 8.474 | 4.484 |
| General & Administrative Expenses
| 15.018 | 12.241 | 10.185 | 6.962 | 10.982 | 14.291 | 17.655 | 14.687 | 8.659 | 4.721 | 2.004 |
| Selling & Marketing Expenses
| 0.264 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 15.282 | 12.241 | 10.185 | 6.962 | 10.982 | 14.291 | 17.655 | 14.687 | 8.659 | 4.721 | 2.004 |
| Other Expenses
| 0 | 0 | 0 | 0.016 | 3,953.273 | 12,736.79 | 0 | -0.163 | -1.88 | 0 | 0 |
| Operating Expenses
| 43.045 | 41.672 | 21.439 | 14.902 | 17.081 | 30.36 | 51.967 | 39.512 | 26.499 | 13.194 | 6.488 |
| Operating Income
| -43.045 | -41.672 | -21.439 | -14.902 | -21.035 | -43.097 | -51.967 | -39.512 | -26.499 | -13.194 | -6.488 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -1.303 | -0.381 | 0.004 | 0.055 | 13.654 | -12.737 | -1.479 | -0.163 | -1.88 | 0.582 | -0.854 |
| Income Before Tax
| -44.348 | -42.054 | -21.435 | -14.847 | -7.38 | -43.65 | -53.446 | -40.667 | -29.186 | -12.792 | -7.342 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 1.406 | -1.199 | -4.516 | -0.136 | -0.382 | -2.782 | -2.586 | -1.846 | -1.107 | -0.591 | -0.459 |
| Net Income
| -42.942 | -40.855 | -16.918 | -14.847 | -6.999 | -40.868 | -50.86 | -38.821 | -28.079 | -12.201 | -6.883 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | -26.16 | -33.47 | -26.9 | -69.43 | -16.15 | -9.11 |
| EPS Diluted
| -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | -26.16 | -33.47 | -26.9 | -69.43 | -16.15 | -9.11 |
| EBITDA
| -42.988 | -40.737 | -21.434 | -14.832 | -16.728 | -29.314 | -51.266 | -39.463 | -28.37 | -13.16 | -6.48 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |